Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 4 recruiting clinical trials
Advanced solid tumors
87890387STM1001
Phase
NCT06178614
Compound
JNJ-87890387 (ENPP3 × CD3 bispecific Ab)
Advanced solid tumors
89862175LUC1001
Phase
NCT07223125
Compound
JNJ-89862175 (ENPP3 ADC)
Advanced solid tumors
95437446LUC1001
Phase
NCT07107230
Compound
JNJ-95437446 (EGFR × MET ADC)
Advanced solid tumors
1761981STM1001
Phase
NCT07525141
Compound
JNJ-1761981 ER (an extended-release chemotherapy)
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; ADC, antibody-drug conjugate; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ENPP3, ectonucleotide pyrophosphatase/phosphodiesterase 3; MET, mesenchymal epithelial transition factor.